[Mechanism and clinical progress of JAK inhibitors in hemophagocytic lymphohistiocytosis].

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome characterized by uncontrolled activation of lymphocytes and macrophages. Owing to its marked etiological heterogeneity, HLH is broadly classified into primary and secondary forms. Janus kinase (JAK) inhibitors, represented by ruxolitinib, exert therapeutic effects by blocking the JAK-STAT signaling pathway and suppressing the secretion of various cytokines, including interferon-γ. Accumulating evidence suggests that JAK inhibitors demonstrate unique therapeutic potential across diverse etiological backgrounds of HLH. This review summarizes the mechanisms and clinical research progress of JAK inhibitors in the treatment of HLH.